Show simple item record

High-risk human papillomavirus distribution according to human immunodeficiency virus status among women with cervical cancer in Abidjan, Cote d'Ivoire, 2018 to 2020

dc.rights.licenseopenen_US
dc.contributor.authorBONI, Simon P
dc.contributor.authorTENET, Vanessa
dc.contributor.authorHORO, Apollinaire
dc.contributor.authorHEIDEMAN, Danielle A M
dc.contributor.authorBLEEKER, Maaike C G
dc.contributor.authorTANON, Aristophane
dc.contributor.authorMIAN, Boston
dc.contributor.authorMOHENOU, Isidore D
hal.structure.identifierBordeaux population health [BPH]
hal.structure.identifierGlobal Health in the Global South [GHiGS]
dc.contributor.authorEKOUEVI, Didier Koumavi
dc.contributor.authorGHEIT, Tarik
dc.contributor.authorDIDI-KOUKO COULIBALY, Judith
dc.contributor.authorTCHOUNGA, Boris K
dc.contributor.authorADOUBI, Innocent
dc.contributor.authorCLIFFORD, Gary M
hal.structure.identifierBordeaux population health [BPH]
hal.structure.identifierGlobal Health in the Global South [GHiGS]
dc.contributor.authorJAQUET, Antoine
dc.date.accessioned2024-01-10T09:00:57Z
dc.date.available2024-01-10T09:00:57Z
dc.date.issued2023-11-09
dc.identifier.issn1097-0215en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/186998
dc.description.abstractEnAs human papillomavirus (HPV) immunisation and HPV-based cervical cancer (CC) screening programmes expand across sub-Saharan Africa, we investigated the potential impact of human immunodeficiency virus (HIV) status on high-risk (HR)-HPV distribution among women with CC in Cote d'Ivoire. From July 2018 to June 2020, paraffin-embedded CC specimens diagnosed in Abidjan, Cote d'Ivoire were systematically collected and tested for HR-HPV DNA. Type-specific HR-HPV prevalence was compared according to HIV status. Of the 170 CC specimens analysed (median age 52 years, interquartile range: [43.0-60.0]), 43 (25.3%) were from women living with HIV (WLHIV) with a median CD4 count of 526 [373-833] cells/mm(3) and 86% were on antiretroviral therapy (ART). The overall HR-HPV prevalence was 89.4% [95% CI: 84.7-94.1]. All were single HR-HPV infections with no differences according to HIV status (P = .8). Among HR-HPV-positive CC specimens, the most prevalent HR-HPV types were HPV16 (57.2%), HPV18 (19.7%), HPV45 (8.6%) and HPV35 (4.6%), with no significant differences according to HIV status. Altogether, infection with HPV16/18 accounted for 71.1% [95% CI: 55.9-86.2] of CC cases in WLHIV vs 78.9% [95% CI: 71.3-86.5] in women without HIV (P = .3). The study confirms the major role of HPV16/18 in CC in Cote d'Ivoire and should support a regional scale-up of HPV16/18 vaccination programmes regardless of HIV status. However, vaccines targeting additional HR-HPV types, including HPV45 and HPV35, could further decrease future CC incidence in Cote d'Ivoire, both for WLHIV and women without HIV.
dc.language.isoENen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.subject.encervical cancer
dc.subject.enCôte d'Ivoire
dc.subject.enhigh-risk human papillomavirus
dc.subject.enhuman immunodeficiency virus
dc.title.enHigh-risk human papillomavirus distribution according to human immunodeficiency virus status among women with cervical cancer in Abidjan, Cote d'Ivoire, 2018 to 2020
dc.title.alternativeInt J Canceren_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1002/ijc.34774en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed37942579en_US
bordeaux.journalInternational Journal of Canceren_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamGHIGS_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.identifier.funderIDEunice Kennedy Shriver National Institute of Child Health and Human Developmenten_US
bordeaux.identifier.funderIDNational Cancer Instituteen_US
bordeaux.identifier.funderIDFogarty International Centeren_US
bordeaux.identifier.funderIDNational Heart, Lung, and Blood Instituteen_US
bordeaux.identifier.funderIDNational Institute on Drug Abuseen_US
bordeaux.identifier.funderIDNational Institute on Alcohol Abuse and Alcoholismen_US
bordeaux.identifier.funderIDNational Institute of Diabetes and Digestive and Kidney Diseasesen_US
bordeaux.identifier.funderIDU.S. National Library of Medicineen_US
bordeaux.identifier.funderIDInstitut de Recherche pour le Développementen_US
hal.identifierhal-04384266
hal.version1
hal.date.transferred2024-01-10T09:01:01Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=International%20Journal%20of%20Cancer&rft.date=2023-11-09&rft.eissn=1097-0215&rft.issn=1097-0215&rft.au=BONI,%20Simon%20P&TENET,%20Vanessa&HORO,%20Apollinaire&HEIDEMAN,%20Danielle%20A%20M&BLEEKER,%20Maaike%20C%20G&rft.genre=article


Files in this item

Thumbnail
Name:
BPH_IntJCancer_2023_Boni.pdf
Size:
579.6Kb
Format:
PDF
View/Open
Thumbnail
Name:
license_rdf
Size:
811bytes
Format:
application/rdf+xml
View/Open

This item appears in the following Collection(s)

Show simple item record